CD7 expression does not predict for poor outcome in acute myeloblastic leukemia.
Pillay
Y
Y
McLellan
G
G
Davison
G
G
Kelly
S
S
Jacobs
P
P
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism*; D019011:Antigens, CD7; D000945:Antigens, Differentiation, T-Lymphocyte / Q000378:metabolism*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D014411:Neoplastic Stem Cells / Q000378:metabolism*; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016176:T-Lymphocyte Subsets / Q000378:metabolism*
D015703:Antigens, CD; D019011:Antigens, CD7; D000945:Antigens, Differentiation, T-Lymphocyte; D003561:Cytarabine; D005047:Etoposide; D003630:Daunorubicin